ADCT vs CTMX
ADCT: ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma. CTMX: CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer.
Side-by-side fundamentals
| Metric | ADCT | CTMX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.24 | $3.33 | |
| Market cap as of 2026-07-23 | $158M | $724M | |
| Net margin as of 2026-07-23 | -173.0% | -166.4% | CTMX higher |
| Gross margin as of 2026-07-23 | +90.7% | n/a | |
| Operating margin as of 2026-07-23 | -149.4% | -181.9% | ADCT higher |
| ROE as of 2026-07-23 | -229.2% | -36.6% | CTMX higher |
| ROA as of 2026-07-23 | -44.7% | -28.0% | CTMX higher |
| Debt / equity as of 2026-07-23 | 9.01 | 0.00 | CTMX lower |
| Revenue growth (YoY) as of 2026-07-23 | +4.4% | -75.9% | ADCT higher |
| Revenue CAGR (3y) SEC XBRL | -27.1% | +12.8% | CTMX higher |
| Beta as of 2026-07-23 | 1.83 | 2.16 | |
| 1-year return as of 2026-07-22 close | -59.6% | +43.7% | CTMX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.